Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration

被引:28
|
作者
Patel, Y. A. [1 ]
Gifford, E. J. [1 ]
Glass, L. M. [1 ]
McNeil, R. [1 ]
Turner, M. J. [1 ]
Han, B. [1 ]
Provenzale, D. [1 ]
Choi, S. S. [1 ]
Moylan, C. A. [1 ]
Hunt, C. M. [1 ]
机构
[1] Duke Univ, Hosp South, Durham, NC 27708 USA
关键词
UNITED-STATES; HEPATOCELLULAR-CARCINOMA; NONINVASIVE DIAGNOSIS; HISTOLOGICAL SEVERITY; BARIATRIC SURGERY; ADVANCED FIBROSIS; NAFLD FIBROSIS; STEATOHEPATITIS; METAANALYSIS; PROGRESSION;
D O I
10.1111/apt.14411
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: With its increasing incidence, nonalcoholic fatty liver disease (NAFLD) is of particular concern in the Veterans Health Administration (VHA). Aims: To evaluate risk factors for advanced fibrosis in biopsy-proven NAFLD in the VHA, to identify patients at risk for adverse outcomes. Methods: In randomly selected cases from VHA databases (2005-2015), we performed a retrospective case-control study in adults with biopsy-defined NAFLD or normal liver. Results: Of 2091 patients reviewed, 399 met inclusion criteria. Normal controls (n = 65) had normal liver function. The four NAFLD cohorts included: NAFL steatosis (n = 76), nonalcoholic steatohepatitis (NASH) without fibrosis (n = 68), NAFLD/NASH stage 1-3 fibrosis (n = 82), and NAFLD/NASH cirrhosis (n = 70). NAFLD with hepatocellular carcinoma (HCC) was separately identified (n = 38). Most patients were older White men. NAFLD patients with any fibrosis were on average severely obese (BMI>35 kg/m(2)). Diabetes (54.4%-79.6%) and hypertension (85.8%-100%) were more common in NAFLD with fibrosis or HCC. Across NAFLD, 12.3%-19.5% were enrolled in diet/exercise programs and 0%-2.6% had bariatric surgery. Hispanics exhibited higher rates of NASH (20.6%), while Blacks had low NAFLD rates (1.4%-11.8%), particularly NAFLD cirrhosis and HCC (1.4%-2.6%). Diabetes (OR 11.8, P < .001) and BMI (OR 1.4, P < .001) were the most significant predictors of advanced fibrosis. Conclusions: In the VHA, diabetes and severe obesity increased risk for advanced fibrosis in NAFLD. Of these patients, only a small proportion (similar to 20%) had enrolled in diet/exercise programs or had bariatric surgery (similar to 2%). These results suggest that providers should focus/tailor interventions to improve outcomes, particularly in those with diabetes and severe obesity.
引用
收藏
页码:268 / 278
页数:11
相关论文
共 50 条
  • [31] Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review
    Bekaert, M.
    Verhelst, X.
    Geerts, A.
    Lapauw, B.
    Calders, P.
    OBESITY REVIEWS, 2016, 17 (01) : 68 - 80
  • [32] The clinical and histological characteristics of patients with biopsy-proven non-alcoholic fatty liver disease in the absence of insulin resistance
    Demirtas, Coskun Ozer
    Sapmaz, Aybuke
    Gurel, Burak Ahmet
    Kizmaz, Hasan
    Ulu, Tuncay
    Karaketir, Seyma Gorcin
    Hidiroglu, Seyhan
    Yilmaz, Yusuf
    HEPATOLOGY FORUM, 2020, 1 (03): : 101 - 108
  • [33] Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes
    Aller de la Fuente, Rocio
    Mora Cuadrado, Natalia
    Tafur, Carla
    Lopez Gomez, Juan Jose
    Gomez de la Cuesta, Sara
    Garcia Sanchez, Maria Concepcion
    Antolin Melero, Beatriz
    de Luis Roman, Daniel Antonio
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2018, 65 (06): : 354 - 360
  • [34] Characteristics and Clinical Outcomes of A Diverse Cohort of Patients with Biopsy-Proven Non-Alcoholic Fatty Liver Disease (NAFLD)
    Yip, Benjamin
    Yee, Brittany E.
    Do, Ailinh
    Nguyen, Nghia H.
    Hoang, Joseph K.
    Nguyen, Mindie H.
    HEPATOLOGY, 2015, 62 : 1303A - 1303A
  • [35] Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome
    Qureshi, K.
    Abrams, G. A.
    CLINICAL OBESITY, 2016, 6 (02) : 117 - 123
  • [36] Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease
    Gao, Feng
    Huang, Jiao-Feng
    Zheng, Kenneth I.
    Pan, Xiao-Yan
    Ma, Hong-Lei
    Liu, Wen-Yue
    Byrne, Christopher D.
    Targher, Giovanni
    Li, Yang-Yang
    Chen, Yong-Ping
    Chan, Wah-Kheong
    Zheng, Ming-Hua
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 (10) : 1804 - 1812
  • [37] ARTERIAL STIFFNESS IS INDEPENDENTLY ASSOCIATED WITH LIVER STIFFNESS IN BIOPSY-PROVEN NON-ALCOHOLIC FATTY LIVER DISEASE: A TRANSIENT ELASTOGRAPHY STUDY
    Bilgin, Beyza Oren
    Sunbul, Murat
    Kani, Haluk Tarik
    Demirtas, Coskun Ozer
    Keklikkiran, Caglayan
    Yilmaz, Yusuf
    HEPATOLOGY, 2019, 70 : 1063A - 1064A
  • [38] Liver biopsy-proven non-alcoholic fatty liver disease predicts no impact on antiviral response in patients with chronic hepatitis B
    Chen, Miao-Yang
    Li, Shun-Xin
    Du, Zhi-Xiang
    Xiong, Qing-Fang
    Zhong, Yan-Dan
    Liu, Du-Xian
    Yang, Yong-Feng
    CLINICS, 2024, 79
  • [39] SARCOPENIA IS AN INDEPENDENT RISK FACTOR FOR BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS
    Kim, W.
    Koo, B. K.
    Joo, S. K.
    Kim, J. H.
    Park, S. C.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S502 - S502
  • [40] The first external validation of the Dallas steatosis index in biopsy-proven Non-alcoholic fatty liver Disease: A multicenter study
    Kouvari, Matina
    Mylonakis, Sophia C.
    Katsarou, Angeliki
    Valenzuela-Vallejo, Laura
    Guatibonza-Garcia, Valentina
    Kokkorakis, Michail
    Verrastro, Ornella
    Angelini, Giulia
    Markakis, Georgios
    Eslam, Mohammed
    George, Jacob
    Papatheodoridis, Georgios
    Mingrone, Geltrude
    Mantzoros, Christos S.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 203